Atara Biotherapeutics/$ATRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Atara Biotherapeutics
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Ticker
$ATRA
Sector
Primary listing
Employees
13
Headquarters
Website
ATRA Metrics
BasicAdvanced
$105m
-
-$0.71
0.11
-
Price and volume
Market cap
$105m
Beta
0.11
52-week high
$19.15
52-week low
$3.92
Average daily volume
90k
Financial strength
Current ratio
2.156
Quick ratio
1.481
Long term debt to equity
-24.325
Total debt to equity
-27.042
Interest coverage (TTM)
-0.70%
Profitability
EBITDA (TTM)
-2.163
Gross margin (TTM)
70.11%
Net profit margin (TTM)
-40.91%
Operating margin (TTM)
-10.86%
Effective tax rate (TTM)
-0.33%
Revenue per employee (TTM)
$1,780,000
Management effectiveness
Return on assets (TTM)
-3.83%
Return on equity (TTM)
20.49%
Valuation
Price to revenue (TTM)
6.733
Price to book
-2.66
Price to tangible book (TTM)
-2.66
Price to free cash flow (TTM)
-6.021
Free cash flow yield (TTM)
-16.61%
Free cash flow per share (TTM)
-1.935
Growth
Revenue change (TTM)
-88.42%
Earnings per share change (TTM)
-60.42%
3-year revenue growth (CAGR)
-26.16%
3-year earnings per share growth (CAGR)
-76.18%
10-year earnings per share growth (CAGR)
-35.78%
What the Analysts think about ATRA
Analyst ratings (Buy, Hold, Sell) for Atara Biotherapeutics stock.
ATRA Financial Performance
Revenues and expenses
ATRA Earnings Performance
Company profitability
ATRA News
AllArticlesVideos
Atara Biotherapeutics Announces Changes to Its Board of Directors
Business Wire·3 weeks ago
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Business Wire·1 month ago
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs